Catalyst Pharma Confirms NASDAQ Listing in 8-K Filing

TL;DR

**Catalyst Pharma just filed an 8-K confirming its stock is still listed on NASDAQ.**

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose that its common stock, with a par value of $0.001 per share, is registered on the NASDAQ Capital Market under Section 12(b) of the Securities Exchange Act of 1934. This filing primarily serves to update administrative information and confirm its listing status. For investors, this filing simply reaffirms the company's continued compliance and trading on a major exchange, which is a basic expectation for a publicly traded company.

Why It Matters

This filing confirms Catalyst Pharmaceuticals' continued listing on the NASDAQ Capital Market, ensuring its stock remains easily tradable for investors.

Risk Assessment

Risk Level: low — This filing is purely administrative and confirms standard listing information, posing no new risks.

Analyst Insight

This filing is administrative and does not provide new information that would warrant an immediate investment action. Investors should continue to monitor operational and financial performance.

Key Numbers

• $0.001 — Par Value per Share (The stated par value of Catalyst Pharmaceuticals' common stock.)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• NASDAQ Capital Market (company) — the exchange where the common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• January 8, 2024 (date) — date of the earliest event reported and filing date

Forward-Looking Statements

• Catalyst Pharmaceuticals will continue to trade on the NASDAQ Capital Market. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: Ongoing

FAQ

From the Filing

0001193125-24-003940.txt : 20240108 0001193125-24-003940.hdr.sgml : 20240108 20240108081000 ACCESSION NUMBER: 0001193125-24-003940 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 24518441 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d108681d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-01-08 2024-01-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure On January 8, 2024, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts, or other parties. The information in this Item 7.01, including Exhibit 99.1, is furnished pursuant to Exhibit 7.01 and shall not be deemed “filed” for purposes of Sec